Aurora Cannabis einfach TOP !!! (Seite 245)
eröffnet am 28.05.18 17:26:58 von
neuester Beitrag 16.05.24 19:32:49 von
neuester Beitrag 16.05.24 19:32:49 von
Beiträge: 14.381
ID: 1.281.132
ID: 1.281.132
Aufrufe heute: 1
Gesamt: 2.460.226
Gesamt: 2.460.226
Aktive User: 0
ISIN: CA05156X8504 · WKN: A4ZZ0W · Symbol: ACB
8,8400
CAD
-5,76 %
-0,5400 CAD
Letzter Kurs 23.05.24 Toronto
Neuigkeiten
TitelBeiträge |
---|
23.05.24 · Hotstock Investor Anzeige |
22.05.24 · Hotstock Investor Anzeige |
21.05.24 · Hotstock Investor Anzeige |
11.05.24 · Roland Jegen Anzeige |
Werte aus der Branche Pharmaindustrie
Wertpapier | Kurs | Perf. % |
---|---|---|
5,0000 | +99.999,00 | |
1,8050 | +44,40 | |
3,4300 | +25,18 | |
0,6000 | +25,00 | |
2,0600 | +24,85 |
Wertpapier | Kurs | Perf. % |
---|---|---|
4,1800 | -11,63 | |
4,8500 | -14,31 | |
0,6460 | -19,25 | |
10,560 | -24,03 | |
0,5120 | -48,80 |
Beitrag zu dieser Diskussion schreiben
!
Dieser Beitrag wurde von FairMOD moderiert. Grund: persönlicher Angriff!
Dieser Beitrag wurde von FairMOD moderiert. Grund: Beleidigung!
Dieser Beitrag wurde von FairMOD moderiert. Grund: persönlicher Angriff!
Dieser Beitrag wurde von CloudMOD moderiert. Grund: auffällige/abwertende Vulgärsprache!
Dieser Beitrag wurde von FairMOD moderiert. Grund: persönlicher Angriff!
Dieser Beitrag wurde von FairMOD moderiert. Grund: persönlicher Angriff
Antwort auf Beitrag Nr.: 62.342.744 von worldtravelthomas am 10.01.20 22:01:53
Unser Depot wird die Anteile von ACB Aktien noch die benötigte Zeit mittragen, da - meiner Meinung nach - die Unternehmensführung mit ihren Partnern zum richtigen Zeitpunkt reagieren muss. Ich erwarte auf und nach der Konferenz erste Nachrichten. Danach werde ich die Position im Depot anpassen.
Zitat von worldtravelthomas:Zitat von T_Schr: ...
Danke Dir für deinen Hinweislink zu dem Artikel bezüglich der anstehenden Befriedigung der Wandelanleihe. Die derzeitige Situation bei ACB ist sicher diesbezüglich sehr unglücklich, doch ich denke der Investor wird im Ergebnis wohl im Anschluss einen noch besseren Geschäftsdeal abschließen, sofern er sich eine starke Vertragsposition herausgearbeitet hat. Prinzipiell haben sich für das wachsende ACB Geschäftsmodell nichts gravierendes verändert. Die Marktentwicklung ist halt schwieriger wie gedacht. In solchen Zeiten braucht es eine gute Managementleistung. Diesbezüglich habe ich mich bei dem Unternehmen allerdings nicht informieren wollen, da meine gehaltene Position zu klein ist um den Aufwand zu rechtfertigen.
Jeder der vor Fälligkeit ende März investiert, oder investiert ist darf sich natürlich dem Risiko aussetzten... ich schau mir das gemütlich von der Seitenlinie an und erfreue mich an meinem Depot. Wenn sich die Sachlage zum guten wendet, kann mann immer noch einsteigen.
Unser Depot wird die Anteile von ACB Aktien noch die benötigte Zeit mittragen, da - meiner Meinung nach - die Unternehmensführung mit ihren Partnern zum richtigen Zeitpunkt reagieren muss. Ich erwarte auf und nach der Konferenz erste Nachrichten. Danach werde ich die Position im Depot anpassen.
!
Dieser Beitrag wurde von CloudMOD moderiert. Grund: bitte das Threadthema beachten, bleiben Sie bitte sachlich und vermeiden Sie Eingriffe in Privatsphäre anderer Personen
Gestern habe ich Aurora angeschrieben. Wollte wissen, was los ist, was sie gegen den dauernd fallenden Kurs zu tun gedenken.
Das ist die Antwort:
Hi Jurgen,
Thank you for reaching out to the Investor Relations team at Aurora. We apologize for the delay in the getting back to you; while we understand your frustration we do ask for your patience as we have worked through a high volume of inquires received over the holidays which has resulted in slightly longer response time.
First off, it goes without saying that the volatility that we have seen in the market is an industry wide issue, not one that is isolated to Aurora. Aurora’s share price has been affected by many factors, a number of which are out of our control (e.g. industry news). That being said, we have also announced a number of changes and decisions over the past few weeks which were made to right size our near term operations to current market conditions, reduce our short term capital expenditures and overall, stream line our business. As a company, we endeavor to provide our shareholders with regular updates, both in press release format (such as our recent corporate update) as well as regular IR blog posts to provide shareholders with greater insight into the company’s day-to-day operations. As I am sure you are aware, I cannot provide you with details as to the future plans of the company, outside of what we have already stated publicly. However I’m happy to review why Aurora is uniquely positioned to weather the current market issues noted above.
With that being said, Aurora’s management team has worked incredibly hard to build an industry leading seed-to-sale business. First, Aurora operates industry leading, state-of-the-art cannabis facilities that produce premium quality cannabis at ultra-low costs, resulting in an our strong gross margins of 58% in Q1 2020. Leveraging high-tech automation in our facilities, our cost per gram during the past quarter was $0.85, an industry leading metric that validates the power of our purpose-built facilities. Aurora’s strength lies in its highly efficient production capabilities and its delivery of industry-leading gross margins. Our margins are core to our future success and will allow us to secure our financial future while continuing to strengthen our operations.
Now a trusted and established supplier of high-quality medical and consumer cannabis products in Canada, Aurora is leading the development of markets around the world. Aurora has established itself as the industry partner of choice securing several supply agreements in the EU and beyond. These supply agreements speak to our ability to navigate complex regulatory systems, build relationships, and execute on the incredible opportunity beyond our borders. Today, the Company has sales and operations in 25 countries across five continents and we continue to monitor the global cannabis markets closely and believe our global expansion to date has positioned us extremely well to capitalize on nascent markets as they emerge.
With respect to R&D, aside from the 40 clinical trials underway with our clinical research team, Aurora has also entered into an exclusive global partnership with the UFC to carryout advanced clinical research on the uses of hemp-derived CBD products in athlete wellness and recovery. The products developed through this partnership will be launched under Aurora’s newly formed high-performance sports brand ROAR Sports. ROAR will also be designated as the official CBD product of UFC.
As announced in the December 23, 2019 press release, we launched regulated vapes, edibles and concentrates in Canada. The new Cannabis 2.0 market represents a promising opportunity for Aurora and we are prepared to supply the market with range of premium products that consumers have come to expect from Aurora. Initial product varieties will include chocolates, gummies, cookies and mints as well as vapes.
Should you have any other questions, please reach out.
Best,
Investor Relations │ Aurora Cannabis
Das ist die Antwort:
Hi Jurgen,
Thank you for reaching out to the Investor Relations team at Aurora. We apologize for the delay in the getting back to you; while we understand your frustration we do ask for your patience as we have worked through a high volume of inquires received over the holidays which has resulted in slightly longer response time.
First off, it goes without saying that the volatility that we have seen in the market is an industry wide issue, not one that is isolated to Aurora. Aurora’s share price has been affected by many factors, a number of which are out of our control (e.g. industry news). That being said, we have also announced a number of changes and decisions over the past few weeks which were made to right size our near term operations to current market conditions, reduce our short term capital expenditures and overall, stream line our business. As a company, we endeavor to provide our shareholders with regular updates, both in press release format (such as our recent corporate update) as well as regular IR blog posts to provide shareholders with greater insight into the company’s day-to-day operations. As I am sure you are aware, I cannot provide you with details as to the future plans of the company, outside of what we have already stated publicly. However I’m happy to review why Aurora is uniquely positioned to weather the current market issues noted above.
With that being said, Aurora’s management team has worked incredibly hard to build an industry leading seed-to-sale business. First, Aurora operates industry leading, state-of-the-art cannabis facilities that produce premium quality cannabis at ultra-low costs, resulting in an our strong gross margins of 58% in Q1 2020. Leveraging high-tech automation in our facilities, our cost per gram during the past quarter was $0.85, an industry leading metric that validates the power of our purpose-built facilities. Aurora’s strength lies in its highly efficient production capabilities and its delivery of industry-leading gross margins. Our margins are core to our future success and will allow us to secure our financial future while continuing to strengthen our operations.
Now a trusted and established supplier of high-quality medical and consumer cannabis products in Canada, Aurora is leading the development of markets around the world. Aurora has established itself as the industry partner of choice securing several supply agreements in the EU and beyond. These supply agreements speak to our ability to navigate complex regulatory systems, build relationships, and execute on the incredible opportunity beyond our borders. Today, the Company has sales and operations in 25 countries across five continents and we continue to monitor the global cannabis markets closely and believe our global expansion to date has positioned us extremely well to capitalize on nascent markets as they emerge.
With respect to R&D, aside from the 40 clinical trials underway with our clinical research team, Aurora has also entered into an exclusive global partnership with the UFC to carryout advanced clinical research on the uses of hemp-derived CBD products in athlete wellness and recovery. The products developed through this partnership will be launched under Aurora’s newly formed high-performance sports brand ROAR Sports. ROAR will also be designated as the official CBD product of UFC.
As announced in the December 23, 2019 press release, we launched regulated vapes, edibles and concentrates in Canada. The new Cannabis 2.0 market represents a promising opportunity for Aurora and we are prepared to supply the market with range of premium products that consumers have come to expect from Aurora. Initial product varieties will include chocolates, gummies, cookies and mints as well as vapes.
Should you have any other questions, please reach out.
Best,
Investor Relations │ Aurora Cannabis
!
Dieser Beitrag wurde von FairMOD moderiert. Grund: persönlicher Angriff04.05.24 · wallstreetONLINE Redaktion · Green Thumb Industries |
01.05.24 · wO Chartvergleich · Rana Gruber |
20.04.24 · wallstreetONLINE Redaktion · Green Thumb Industries |
09.04.24 · wallstreetONLINE Redaktion · Tilray Brands |
08.04.24 · wallstreetONLINE Redaktion · Tilray Brands |
29.03.24 · wallstreetONLINE Redaktion · Constellation Brands (A) |
Zeit | Titel |
---|---|
24.01.24 |